Mark Albert Scheideler

Title: Mark Albert Scheideler: Innovator in Neuropathy Research

Introduction

Mark Albert Scheideler is a notable inventor based in Silver Spring, MD (US). He has made significant contributions to the field of neuropathy research, particularly in relation to Charcot-Marie-Tooth disease 2A (CMT2A). His innovative work has implications for understanding and treating this debilitating condition.

Latest Patents

Scheideler holds a patent for "Rat models for CMT2A that develop a progressive neuropathy." This invention relates to the p.Arg364Trp and p.His361Tyr Mfn2 mutations, which are associated with severe, early-onset axonal neuropathy. The research involved characterizing cohorts of mutant and wild-type rats, revealing multiple motor deficits that worsened over time. The findings provide a valuable model for examining the pathogenesis and potential treatments for CMT2A.

Career Highlights

Throughout his career, Scheideler has worked with prominent organizations, including the Charcot-Marie-Tooth Association and the University of Pennsylvania. His research has focused on the mechanisms of neuropathy and the development of effective therapeutic strategies.

Collaborations

Scheideler has collaborated with esteemed colleagues such as Guojun Zhao and John Svaren. Their combined expertise has further advanced the understanding of CMT2A and its impact on patients.

Conclusion

Mark Albert Scheideler's contributions to neuropathy research, particularly through his patent on rat models for CMT2A, highlight his commitment to advancing medical science. His work continues to pave the way for future innovations in the treatment of this challenging disease.